Financial Contrast: BioLife Solutions (NASDAQ:BLFS) and DiaSorin (OTCMKTS:DSRLF)

BioLife Solutions (NASDAQ:BLFS) and DiaSorin (OTCMKTS:DSRLF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Insider and Institutional Ownership

93.2% of BioLife Solutions shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

BioLife Solutions has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, DiaSorin has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500.

Valuation and Earnings

This table compares BioLife Solutions and DiaSorin”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$82.25 million	15.49	-$20.18 million	($0.12)	-221.58
DiaSorin	$1.28 billion	N/A	$203.55 million	N/A	N/A

DiaSorin has higher revenue and earnings than BioLife Solutions.

Profitability

This table compares BioLife Solutions and DiaSorin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-5.39%	0.16%	0.14%
DiaSorin	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for BioLife Solutions and DiaSorin, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1	0	7	1	2.89
DiaSorin	0	1	2	0	2.67

BioLife Solutions presently has a consensus target price of $31.29, suggesting a potential upside of 17.66%. Given BioLife Solutions’ stronger consensus rating and higher probable upside, research analysts clearly believe BioLife Solutions is more favorable than DiaSorin.

Summary

BioLife Solutions beats DiaSorin on 9 of the 12 factors compared between the two stocks.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.